Molecule News and Research

RSS

What makes H5N1 a pandemic risk and how can we stop it?

A new PEARLS article in PLoS Pathogens reviews the rapid evolution and pandemic potential of emerging influenza A viruses, with a focus on H5N1. It highlights scientific advances and future strategies to outpace the virus, from next-generation vaccines to AI-driven antiviral discovery.

19 May 2025

Red blood cells drive blood vessel damage in diabetes by exporting toxic vesicles

Red blood cell-derived extracellular vesicles in type 2 diabetes are actively taken up by the endothelium, transferring the enzyme arginase-1 and triggering oxidative stress. This mechanism helps explain vascular complications in diabetes and offers new targets for therapeutic intervention.

19 May 2025

Study uncovers common trigger across gene mutations that cause ALS

Using the gene scissors CRISPR and stem cells, researchers at Stockholm University and the UK Dementia Research Institute (UK DRI) at King's College London have managed to identify a common denominator for different gene mutations that all cause the neurological disease ALS.

19 May 2025

Newly discovered Cat1 protein halts viral infections by depleting cellular fuel

Every living creature on Earth needs to protect itself from things that would do it harm. Bacteria are no different. And despite their relative simplicity, they deploy remarkably savvy defensive strategies against viral invaders.

18 May 2025

Optimer licensing agreements and repeat custom

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced two new development contracts for Optimer binders and the agreement of licensing heads of terms with a global provider of specialty enzymes for developed enzyme-modulating Optimers.

From Aptamer Group 16 May 2025

Ubrogepant relieves early migraine symptoms and may help prevent full-blown attacks

A phase 3 trial found that ubrogepant, given during the premonitory phase of migraine, improved common warning symptoms such as fatigue, light and sound sensitivity, and neck pain. These benefits were observed as early as one hour post-treatment, suggesting early intervention can reduce migraine burden.

15 May 2025

Hyaluronidase-1 emerges as a key regulator of postmeal blood sugar

A recent study published in Life Metabolism has uncovered a surprising new player in the body's ability to regulate blood sugar after eating.

15 May 2025

Novel nanoparticle could make ultrasound-based cancer treatments more effective and safer

Researchers have created a new kind of nanoparticle that could make ultrasound-based cancer treatments more effective and safer, while also helping prevent tumors from coming back.

14 May 2025

Study reveals how yellow fever vaccine triggers strong immune response

Researchers show how specific immune cells are activated by the vaccine - an important starting point for the development of new vaccines.

14 May 2025

New approach directly combats the progression of Alzheimer’s and ALS

Scientists at Northwestern University have developed a new approach that directly combats the progression of neurodegenerative diseases like Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

14 May 2025

New glycopeptide antibiotic discovered to combat resistant bacteria

An international team of researchers, led by the University of Vienna and the Helmholtz Institute for Pharmaceutical Research Saarland, has discovered saarvienin A, a new type of glycopeptide antibiotic.

14 May 2025

Skin microbiome plays active role in sun protection and immune balance

The skin microbiome plays an important role in health and disease. Researchers have now substantiated that certain skin bacteria can protect us from the sun's ultraviolet (UV) radiation specifically by metabolizing cis-urocanic acid using an enzyme called urocanase.

13 May 2025

Review spotlights MYC as a multidimensional therapeutic target in cancer

A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and progression of cancer, spotlighting its potential as a multidimensional therapeutic target.

12 May 2025

Breakthrough discovery offers hope for treating neurodegenerative diseases

Researchers have discovered how to block cells dying, in a finding that could lead to new treatments for neurodegenerative conditions like Parkinson's and Alzheimer's.

12 May 2025

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined its Board as Chair, and Stephen Dilly as Non-Executive Director.

From PhoreMost 12 May 2025